Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Applying a clinical lens to animal models of CAR-T cell therapies
Brynn B. Duncan, Cynthia E. Dunbar, Kazusa Ishii
Molecular Therapy — Methods & Clinical Development (2022) Vol. 27, pp. 17-31
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Steven Μ. Albelda
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 1, pp. 47-66
Closed Access | Times Cited: 160
Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection
Wenli Mu, Vaibhavi Patankar, Scott G. Kitchen, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 219-219
Open Access | Times Cited: 13
Cooperative CAR targeting to selectively eliminate AML and minimize escape
Sascha Haubner, Jorge Mansilla‐Soto, Sarah Nataraj, et al.
Cancer Cell (2023) Vol. 41, Iss. 11, pp. 1871-1891.e6
Open Access | Times Cited: 36
Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells
Tengku Ibrahim Maulana, Claudia Teufel, Madalena Cipriano, et al.
Cell stem cell (2024) Vol. 31, Iss. 7, pp. 989-1002.e9
Open Access | Times Cited: 10
Aging impairs CD8 T cell responses in adoptive T-cell therapy against solid tumors
Gulfiya Kadyrzhanova, Miho Tamai, Shukla Sarkar, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
A Novel Tumor on Chip Mimicking the Breast Cancer Microenvironment for Dynamic Drug Screening
M Testa, Miriam Gaggianesi, Caterina D’Accardo, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1028-1028
Open Access
CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma
Laura M. Moser, Catrin Heim, Sebastian E. Koschade, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
RevCAR-mediated T-cell response against PD-L1-expressing cells turns suppression into activation
Eugenia Crespo, Liliana R. Loureiro, Antonia Stammberger, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products
Hammodah R. Alfar, Cecil Chen, Eric J. Lachacz, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype
Eider Moreno-Cortes, Pedro Franco-Fuquen, Juan Esteban García-Robledo, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 12
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment
Thuỳ Anh Bùi, Haoqi Mei, Rui Sang, et al.
EBioMedicine (2024) Vol. 106, pp. 105266-105266
Open Access | Times Cited: 4
DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma
Allison M. Kirk, Jeremy Chase Crawford, Ching‐Heng Chou, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 3, pp. 101469-101469
Open Access | Times Cited: 3
IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
Hongtai Shi, Andi Li, Zhenyu Dai, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Cell Granularity Reflects Immune Cell Function and Enables Selection of Lymphocytes with Superior Attributes for Immunotherapy
Tongjin Wu, Joel Heng Loong Tan, Wei‐Xiang Sin, et al.
Advanced Science (2023) Vol. 10, Iss. 28
Open Access | Times Cited: 9
Development of chimeric antigen receptor (CAR)-T cells targeting A56 viral protein implanted by oncolytic virus
Euna Cho, Min Ho An, Yi Sle Lee, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109256-109256
Open Access | Times Cited: 2
Non-viral vectors for chimeric antigen receptor immunotherapy
Sandy Tretbar, Joel G. Rurik, Even H Rustad, et al.
Nature Reviews Methods Primers (2024) Vol. 4, Iss. 1
Closed Access | Times Cited: 2
DMPK perspective on quantitative model analysis for chimeric antigen receptor cell therapy: Advances and challenges
Akihiko Goto, Yuu Moriya, Miyu Nakayama, et al.
Drug Metabolism and Pharmacokinetics (2024) Vol. 56, pp. 101003-101003
Open Access | Times Cited: 1
Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model
Tahereh Soltantoyeh, Behnia Akbari, Zahra Shahosseini, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Engineering strategies to mitigate toxicities associated with CAR‐T cell therapy
Tyler Wolter, Yixin Wang, Quanyin Hu
BMEMat (2024)
Open Access | Times Cited: 1
Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system
Peter S. Chang, Yi‐Chun Chen, Wei‐Kai Hua, et al.
PLoS ONE (2024) Vol. 19, Iss. 8, pp. e0309245-e0309245
Open Access | Times Cited: 1
Evolving strategies for addressing CAR T-cell toxicities
Alexander W. Rankin, Brynn B. Duncan, Cecily Allen, et al.
Cancer and Metastasis Reviews (2024) Vol. 44, Iss. 1
Open Access | Times Cited: 1
Clinical Pharmacology and Translational Considerations in the Development of CRISPR‐Based Therapies
Ahmed M. Abdelhady, Jonathan A. Phillips, Yuanxin Xu, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 3, pp. 591-603
Closed Access | Times Cited: 3
Canadian Regulatory Framework and Regulatory Requirements for Cell and Gene Therapy Products
Jian Wang, Emily Griffiths, Omar Tounekti, et al.
Advances in experimental medicine and biology (2023), pp. 91-116
Closed Access | Times Cited: 3
Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma
Kun Ma, Ping Hu
Cancers (2023) Vol. 15, Iss. 23, pp. 5652-5652
Open Access | Times Cited: 3
Toward the clinical development of synthetic immunity to cancer
Julie Garcia, Cassandra E. Burnett, Kole T. Roybal
Immunological Reviews (2023) Vol. 320, Iss. 1, pp. 83-99
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top